The global women's health market is a dynamic sector focused on addressing healthcare needs specific to women. Encompassing a spectrum of conditions and services, it spans reproductive health, gynecological issues, maternal care, and menopausal health. The market is marked by advancements in diagnostic technologies, therapeutic interventions, and preventive measures tailored for women. Women's health encompasses pharmaceuticals, medical devices, and healthcare services, with a growing emphasis on personalized and holistic care approaches. As healthcare systems worldwide prioritize gender-specific health concerns, the global women's health market continues to evolve, offering a comprehensive range of solutions to enhance and safeguard the well-being of women across different life stages.
Data Bridge Market Research analyses that the Global Women’s Health Market which was USD 4,000.00 million in 2022, is expected to reach USD 6,200.00 million by 2030, and is expected to undergo a CAGR of 5.5% during the forecast period of 2023 to 2030.
"Increase adoption of unhealthy lifestyle drive the market growth"
The global women's health market is propelled by the increasing adoption of unhealthy lifestyle habits among women over 60 and the development of targeted medicines. As this demographic group grows, ailments such as osteoporosis, osteoarthritis, anemia, menstrual health abnormalities, depression, and obesity become more prevalent. The focus on creating specialized medications for women's health concerns is expected to drive market expansion, addressing the specific healthcare needs associated with these prevalent and diverse health issues.
What restraints the growth of the global women’s health market?
"High costs hamper the market growth"
The women's health sector faces a significant restraint due to the exorbitant costs linked to medications. Affordability challenges hinder access to essential treatments, exacerbating healthcare disparities. The high financial burden associated with women's medicines poses a substantial barrier, limiting the widespread availability and utilization of critical healthcare interventions.
Segmentation: Global Women’s Health Market
The global women’s health market is segmented on the basis of drugs and application.
- On the basis drugs, the global women’s health market is segmented into Prolia, XGEVA, EVISTA, Mirena, Zometa, Reclast or Aclasta, Minastrin 24 Fe, FORTEO, NuvaRing, Primarin, ACTONEL, and ORTHO TRI-CY LO (28)
- On the basis of application, the global women’s health market is segmented into hormonal infertility, female infertility, postmenopausal osteoporosis, endometriosis, contraception, polycystic ovary syndrome (PCOS), menopause, and other
Regional Insights: North America dominates the Global Women’s Health Market
North America dominates the global women's health market, propelled by a robust network of testing facilities and the substantial presence of major industry players. The region witnesses a surge in cases of women's disorders, contributing to market leadership. Additionally, the escalating number of research activities further strengthens North America's position, fostering advancements in women's health diagnostics, treatments, and preventive measures.
Asia-Pacific is expected to dominate the global women's health market from 2023 to 2030. This dominance is attributed to increased government initiatives fostering awareness, burgeoning research activities, untapped markets, a substantial population, and a rising demand for quality healthcare. As these factors converge, the region becomes a focal point for advancements in women's health, indicating significant growth potential and a pivotal role in shaping the trajectory of global women's healthcare initiatives.
Recent Developments: Global Women’s Health Market
- In December 2020, Pfizer, Inc. entered a collaboration with Myovant Sciences to commercialize and develop Relugolix, the inaugural oral GnRH antagonist for oncology and women's health, expanding Pfizer's commitment to advancing innovative solutions in these critical medical domains
- In September 2020, Bayer augmented its women's healthcare product portfolio by acquiring KaNDy Therapeutics Ltd., reinforcing its dedication to addressing diverse health needs and furthering advancements in women's health
To know more about the study, visit https://www.databridgemarketresearch.com/es/reports/global-womens-health-market
The Prominent Key Players Operating in the Global Women’s Health Market Include:
- Siemens (Germany)
- Hologic, Inc. (U.S.)
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
- Abbott (U.S.)
- BD (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Thermo Fisher Scientific Inc. (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- NeuroLogica Corp. (U.S.)
- Shimadzu Medical pvt. Ltd. (Japan)
- GENERAL ELECTRIC (U.S.)
- Quest Diagnostics Incorporated (U.S.)
- Sysmex India Pvt. Ltd. (Japan)
- Hitachi, Ltd. (Japan)
- Canon Inc. (Japan)
- FUJIFILM Holdings Corporation (U.K.)
Above are the key players covered in the report, to know about more and exhaustive list of global women’s health market companies, contact: https://www.databridgemarketresearch.com/es/contact
Research Methodology: Global Women’s Health Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
